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The generation of non-thienamycin-producing mutants with mutations in the thnL, thnN, thnO, and thnI
genes within the thn gene cluster from Streptomyces cattleya and their involvement in thienamycin biosynthesis
and regulation were previously reported. Four additional mutations were independently generated in the thnP,
thnG, thnR, and thnT genes by insertional inactivation. Only the first two genes were found to play a role in
thienamycin biosynthesis, since these mutations negatively or positively affect antibiotic production. A muta-
tion of thnP results in the absence of thienamycin production, whereas a 2- to 3-fold increase in thienamycin
production was observed for the thnG mutant. On the other hand, mutations in thnR and thnT showed that
although these genes were previously reported to participate in this pathway, they seem to be nonessential for
thienamycin biosynthesis, as thienamycin production was not affected in these mutants. High-performance
liquid chromatography (HPLC)-mass spectrometry (MS) analysis of all available mutants revealed some
putative intermediates in the thienamycin biosynthetic pathway. A compound with a mass corresponding to
carbapenam-3-carboxylic acid was detected in some of the mutants, suggesting that the assembly of the bicyclic
nucleus of thienamycin might proceed in a way analogous to that of the simplest natural carbapenem,
1-carbapen-2-em-3-carboxylic acid biosynthesis. The accumulation of a compound with a mass corresponding
to 2,3-dihydrothienamycin in the thnG mutant suggests that it might be the last intermediate in the biosyn-
thetic pathway. These data, together with the establishment of cross-feeding relationships by the cosynthesis
analysis of the non-thienamycin-producing mutants, lead to a proposal for some enzymatic steps during
thienamycin assembly.
The -lactam family is the most important class of antibiot-
ics for clinical use as antimicrobial agents and constitutes a
major part of the global antibiotic market (6). This family
includes penicillins, cephalosporins, carbapenems, and cla-
vams. The basis of the selective toxicity of -lactams is their
role as inhibitors of bacterial cell wall peptidoglycan biosyn-
thesis. Carbapenem antibiotics constitute a nonconventional
class of -lactams, produced by streptomycetes and Gram-
negative bacteria, with important clinical applications, partic-
ularly in infections mediated by multidrug-resistant bacteria.
They show a broad spectrum of activity and are highly resistant
to most of the clinically encountered bacterial -lactamases.
Although the classical -lactams (penicillins and cephalospo-
rins) and their precursors are industrially produced by fermen-
tation and semisynthesis (9), such a methodology has not been
developed for clinically used carbapenems.
Thienamycin (Fig. 1A), the first carbapenem described (14),
is the most potent and broadest in spectrum of all natural
antibiotics known so far (6). It plays an important clinical role
in the treatment of severe nosocomial infectious diseases, as it
is active against aerobic and anaerobic bacteria, both Gram
positive and Gram negative, including Pseudomonas species.
Thienamycin was isolated from a soil species named Strepto-
myces cattleya NRRL 8057 (14), which interestingly also syn-
thesizes the cephalosporin cephamycin C. However, owing to
the low titers of thienamycin production and its chemical in-
stability, commercial production by fermentation is problem-
atic. A more stable derivative produced by chemical synthesis,
named imipenem (N-formidoylthienamycin), is the product of
choice for clinical use. Imipenem and other clinically useful
carbapenems (meropenem, ertapenem, and doripenem, etc.)
are currently made by total organic synthesis, and they are
among the most expensive antibiotics on the market. Hence,
there is interest in an understanding of the genetics and bio-
chemistry of carbapenem biosynthesis to develop fermenta-
tion-based semisynthetic methodologies for the production of
carbapenem antibiotics or intermediates useful for their prep-
aration (8). Although the biosynthetic pathways leading to the
bicyclic nuclei of penicillins, cephalosporins, and the clavam
clavulanic acid have been extensively studied (for a review, see
reference 19), the pathways for the highly substituted carbap-
enems, such as thienamycin, are less well understood.
Several carbapenem gene clusters have been identified from
producer organisms, contributing to the knowledge of biosyn-
thesis and regulation of these antibiotics (for a review, see
reference 4). Carbapenems are biosynthesized via a different
metabolic pathway than that of the classical -lactams. Instead
of the condensation of precursors by an ACV [-(L--amino-
adipyl)-L-cysteinyl-D-valine] synthetase followed by cyclization
by an isopenicillin N synthetase (IPNS), -lactam ring forma-
tion in carbapenems occurs through an alternative mechanism
involving a -lactam synthetase. The gene cluster (car) for the
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simplest natural carbapenem, 1-carbapen-2-em-3-carboxylic
acid (Fig. 1A and B), was first discovered in the plant pathogen
Pectobacterium carotovorum (formerly Erwinia carotovora)
(22). Similar clusters have since been found in both the oppor-
tunistic human pathogen Serratia marcescens (5) and the ento-
mopathogenic bacterium Photorhabdus luminescens (7). Nine
genes comprise the cluster; five of them are structural genes
(carABCDE), although only three genes (carABC) are abso-
lutely required for carbapenem-3-carboxylic acid (Car) biosyn-
thesis (18, 23): CarB catalyzes the first step in the pathway,
generating the pyrrolidine ring after precursor condensation;
CarA catalyzes the formation of the -lactam ring; and, finally,
CarC converts the carbapenam to carbapenem (for details, see
reference 4). CarD and CarE were proposed previously to
catalyze the oxidation of L-proline to provide L-glutamate
semialdehyde (L-GSA) (31) as a precursor for the condensa-
tion reaction catalyzed by CarB. The CarF and CarG proteins
are involved in -lactam resistance, and the role of CarH is still
unknown. CarR is a transcriptional activator involved in the
regulation of the gene cluster.
The gene cluster (thn) for the biosynthesis of the complex
carbapenem thienamycin (Fig. 1A and C) was cloned from S.
cattleya (25), opening up the possibility to study its biosynthesis
and regulation. After in silico sequence analysis, putative roles
were assigned to the gene products. The hypothetical physical
boundaries of the thn cluster were initially established as lying
beyond the region spanning from thnA to thnV, as judged by
the generation of thienamycin-producing mutants in the flank-
ing regions. The involvement in thienamycin biosynthesis was
demonstrated after the independent mutagenesis of the struc-
tural thnL, thnN, and thnO genes (25) and the regulatory gene
thnI (27). A previously reported bioinformatic analysis re-
vealed ThnE and ThnM as likely homologues of CarB and
CarA, respectively (25). Recent advances in the study of the
biochemistry of some thienamycin enzymatic steps, mainly by
in vitro studies with recombinant thn gene products, have con-
tributed to a better understanding of the biosynthetic pathway.
ThnE, which encodes a carboxymethylproline synthase, was
functionally reported to be responsible for pyrrolidine ring
formation in the first step of thienamycin biosynthesis (13).
ThnG and ThnQ are members of the same family as CarC, and
they have been postulated to catalyze reactions analogous to
those of CarC (13, 30). A tentative biosynthetic pathway for
the cysteaminyl side chain of thienamycin, in which coenzyme
A (CoA) (after the incremental cleavage by ThnR, ThnH, and
ThnT) appears to be the source of cysteamine, was proposed
(12). In addition, ThnF was found to be most likely responsible
for the formation of the S. cattleya cometabolite N-acetylth-
ienamycin in the presence of acetyl-CoA (12). Recombinant
versions of ThnG and ThnQ were recently shown to generate
in vitro structural diversity in carbapenem antibiotics (2).
Several recent findings in this area concern the regulation of
thienamycin biosynthesis. ThnI is a LysR-type transcriptional
regulator which constitutes a key factor in controlling thien-
FIG. 1. Carbapenems and biosynthetic gene clusters. (A) Chemical structure of 1-carbapenem-2-em-3-carboxylic acid (Car) and thienamycin
and enzymes proposed to be involved in carbapenem ring formation. (B) Organization of the car gene cluster for Car biosynthesis in Pectobacterium
carotovorum. The arrows indicate the order and direction of the transcription of the genes. (C) Organization and putative physical boundaries of
the thn gene cluster for thienamycin biosynthesis in S. cattleya. Arrows indicate the order and direction of the transcription of the previously
described thn gene cluster (25). Among them, gray arrows represent the ThnI-dependent genes integrating the ThnI regulon (27, 28). The
cross-hatched arrow indicates a gene not required for thienamycin biosynthesis but essential for cephamycin biosynthesis (27), here named cphU
(formerly thnU). White diamonds represent previously generated mutants affected in thienamycin production. Black diamonds indicate mutants
generated in this work. The shaded diamond indicates a previously generated mutant affected in cephamycin C production. Small arrows indicate
promoter regions identified (see the text for details).
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amycin biosynthesis. It is involved in the regulation of a sub-
group of 10 genes in the thn cluster, which constitute the ThnI
regulon (27, 28). A putative model for the mechanism of ThnI
regulation has been proposed, in which ThnI appears to in part
positively autoregulate its own expression (28). However, the
regulation of the remaining genes of the cluster is still un-
known. Surprisingly, a regulatory gene linked to the thn gene
cluster, thnU, turned out to be involved in cephamycin C bio-
synthesis and not in thienamycin biosynthesis. This gene has
been renamed as a cephamycin biosynthesis gene and will here
be designated cphU (Fig. 1C). CphU is a Streptomyces antibi-
otic regulatory protein (SARP) pathway-specific transcrip-
tional activator that regulates the expression of the nonlinked
cephamycin structural genes pcbAB and cmcI (27).
The aim of this work was to gain further insight into the char-
acterization of the thienamycin biosynthetic pathway in S. cattleya
and determine the genes essential for thienamycin biosynthesis.
High-performance liquid chromatography (HPLC)-mass spec-
trometry (MS) analysis and cross-feeding relationships of several
mutants of thn genes revealed some putative intermediates and
the order of some enzymatic steps in the biosynthetic pathway. An
increase in thienamycin production was found for one of the
structural gene mutants. In addition, we provide evidence sup-
porting that some genes previously reported to be part of the
thienamycin gene cluster are not essential for thienamycin bio-
synthesis.
MATERIALS AND METHODS
Bacterial strains, culture conditions, and cloning vectors. Streptomyces cattleya
NRRL 8057, the thienamycin and cephamycin C producer, was used in this study.
The S. cattleya thnL, thnN, thnO, and thnI non-thienamycin-producing mutants
(25, 27) and the thnD-cphU non-thienamycin- and non-cephamycin-producing
mutant (L. E. Nu´n˜ez, unpublished data) were also included in this work (Fig.
1C). Escherichia coli DH10B (Invitrogen) was used as a cloning host. E. coli
ET12567 (dam dcm hsdS), as a source of nonmethylated DNA (20) to prevent
plasmid degradation by the methylation restriction system of S. cattleya, was
used, harboring pUB307 (11) as the donor for intergeneric conjugation. Staph-
ylococcus aureus ATCC 6538P, a thienamycin-sensitive and cephamycin C-resis-
tant strain, and E. coli ESS, a strain supersensitive to all -lactams, were used for
bioassays. For sporulation, S. cattleya bacteria were grown in Bennet medium,
and for antibiotic production, S. cattleya bacteria were grown in R5A-minus
sucrose medium using an inoculum previously grown in tryptic soy broth (TSB)
medium (Merck), as previously described (27). Cosmid cosCAT25 (25) was used
as a source of S. cattleya thn gene cluster DNA. The apramycin resistance-
encoding gene aac(3)IV was obtained from pEFBA (10) and pUO9090 (M. C.
Martín, unpublished results). pUC18 (Pharmacia), pBSK (Stratagene), and
pUK21 (34) were used as E. coli cloning vectors, and cosmid pHZ1358 (32) was
used for E. coli-S. cattleya intergeneric conjugation. When needed, antibiotics
were added to a final concentration of 25 g/ml for thiostrepton, apramycin,
kanamycin, chloramphenicol, or nalidixic acid; 100 g/ml for ampicillin; and 20
g/ml for tobramycin.
DNA manipulations, sequencing, and analysis. Total DNA isolation, plasmid
DNA preparations, restriction endonuclease digestions, ligations, and other
DNA manipulations were performed according to standard procedures for E.
coli (29) and for Streptomyces (16). Intergeneric conjugation from E. coli
ET12567/pUB307 into S. cattleya was done according to procedures previously
described (21). Southern analysis, hybridization, and detection were performed
according to procedures reported previously (29), and the labeling of DNA
probes was performed with digoxigenin (DIG) using the DIG DNA labeling and
detection kit (Roche). DNA sequencing was performed on double-stranded
DNA templates by using the dideoxynucleotide chain termination method and
the Thermo Sequenase labeled primer cycle sequencing kit with 7-deaza-dGTP
(Amersham Biosciences) and an ALF-Express automatic DNA sequencer (Phar-
macia). Computer-assisted database searching and sequence analyses were made
by using the GCG sequence analysis software package from the University of
Wisconsin Genetics Computer Group and the BLAST program (1).
Gene replacement experiments. As a general rule for insertional inactivation,
gene replacement experiments were carried out by the insertion of the aac(3)IV
gene encoding the apramycin resistance cassette. In all cases, the aac(3)IV gene
was inserted within the coding region of the gene to be mutagenized and in the
same direction of transcription. The introduction of DNA into S. cattleya was
achieved by using the bifunctional cosmid pHZ1358 (32) through intergeneric
conjugation from E. coli ET12567/pUB307 as described previously (21). After
the introduction of the construct into S. cattleya by intergeneric conjugation,
transconjugants in which a double crossover occurred were identified by their
resistance to apramycin and susceptibility to thiostrepton.
(i) Mutagenesis of thnP. To generate a mutant containing a thnP deletion
mutation, a 6.5-kb BglII-BamHI DNA fragment carrying thnP from cosCAT25
was cloned into pUK21 previously digested with the same restriction enzymes.
The resulting plasmid was digested with EcoRI, and the generated sticky ends
were filled in with Klenow polymerase to obtain blunt ends. The aac(3)IV gene
(apramycin resistance cassette) obtained from pEFBA, after EcoRV-SmaI di-
gestion (blunt ends), was then inserted into the blunt-ended EcoRI located
within the thnP coding region. An 8-kb insert from this construct was isolated
after SpeI digestion and cloned into the XbaI-digested conjugative vector
pHZ1358 to generate pHZLE7F, which was introduced into S. cattleya to gen-
erate the thnP disruption mutant by gene replacement via homologous recom-
bination (Fig. 2A).
(ii) Mutagenesis of thnG. To construct a mutant containing a thnG disruption
mutation, a 5.8-kb fragment carrying thnG was cloned from cosCAT25 into
pUC18 previously digested with the same restriction enzymes. The resulting
plasmid was digested with BsaAI located within the thnG coding region. The
apramycin resistance cassette, obtained from pEFBA as a BamHI (blunt ended)-
SmaI fragment, was then inserted into the BsaAI-digested plasmid. A 7.3-kb
EcoRI-HindIII fragment was subcloned into pBSK previously digested with the
same enzymes. The fragment was then obtained after BamHI digestion of this
construct and cloned into BamHI-digested pHZ1358 to generate pHZLE1cF,
which was then introduced into S. cattleya to generate the thnG disruption
mutant (Fig. 2B).
(iii) Mutagenesis of thnT. To generate a mutant containing a deletion in the
thnT coding region, two fragments of approximately 2 kb containing part of thnT
and the flanking genes MR1 and MR2 were amplified from cosCAT25 by PCR
with high-fidelity Pfx DNA polymerase (Invitrogen) using primer pairs MR1-F/
MR1-R and MR2-F/MR2-R, respectively. MR1 and MR2 carry synthetic restric-
tion sites (BglII-SphI and NotI-XbaI, respectively) to facilitate cloning into
pUO9090 at both sites of the apramycin resistance cassette (Apr)-encoding gene,
aac(3)IV. The amplified MR1 fragment was digested with BglII-SphI and cloned
into pUO9090, previously digested with the same restriction enzymes, upstream
of aac(3)IV, resulting in pUOMR1apr. In the next step, the amplified MR2
fragment was digested with NotI-XbaI and cloned into pUOMR1apr, previously
digested with the same restriction enzymes, downstream of aac(3)IV. Finally, the
resulting construct, pUOMR1aprMR2, was digested with SpeI and the
MR1aprMR2 fragment (5.5 kb) recovered after agarose gel electrophoresis,
blunt ended with Klenow polymerase (Roche), and cloned into the BamHI-
digested (blunt-ended) conjugative vector pHZ1358 to generate pHZMRT. This
plasmid was introduced into S. cattleya to generate a thnT deletion mutant
(Fig. 2C).
(iv) Mutagenesis of thnR. To construct a mutant containing a thnR disruption
mutation, a 3.9-kb BamHI-SphI fragment comprising thnR and the flanking
genes was cloned from cosCAT25 into pUC18 previously digested with the same
restriction enzymes. The resulting plasmid was digested with AgeI and blunt
ended with Klenow polymerase. Afterwards, the apramycin resistance cassette
(1.5 kb), isolated from pEFBA as an EcoRV-SmaI blunt-end fragment, was
inserted into the AgeI site (blunt ended) located within the thnR coding region.
A 5.4-kb fragment was isolated after PvuI digestion, blunt ended, and cloned into
BamHI-digested (blunt-ended) vector pHZ1358 to generate pHZMR2R. This
plasmid was introduced into S. cattleya to generate a thnR disruption mutant
(Fig. 2D).
Cross-feeding bioassays. Cross-feeding occurs when a mutant blocked at an
earlier step in the pathway converts an intermediate produced by a mutant
blocked at a later step in the pathway, resulting in thienamycin production. The
cross-feeding experiments were performed mainly as described previously (3,
26). Spore suspensions (20 l) of non-thienamycin-producing mutants were
analyzed by pairs and inoculated close to each other (20 mm) onto R5A-minus
sucrose agar plates to establish cross-feeding relationships. After 6 to 10 days of
incubation at 28°C, agar strips containing both mutants were cut out and ana-
lyzed by a bioassay. The strips were placed onto TSA1/2 (half of the concentra-
tion of all components of tryptic soy agar) containing S. aureus ATCC 6538P as
the indicator organism to determine whether the diffusional exchange of accu-
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mulated intermediates restored the thienamycin production ability of the tested
mutants. Inhibition zones or halos corresponding to the restoration of thiena-
mycin production were detected after 1 day of incubation at 37°C.
Analysis of thienamycin and cephamycin C production. Thienamycin produc-
tion was determined by a bioassay using thienamycin-sensitive S. aureus strain
ATCC 6538P (cephamycin C resistant) as an indicator. The thienamycin con-
centration was determined with imipenem, the N-formidoyl derivative of thiena-
mycin, as a standard. Cephamycin C production was assayed by using the -lac-
tam-supersensitive E. coli strain ESS. The identification and quantitative analysis
of thienamycin and cephamycin C production were performed by HPLC-MS
using chromatographic equipment formed by an Alliance separation module,
photodiode array detector 9965, and a ZQ 4000 mass spectrometer (Micromass;
Waters). Acetonitrile and 0.1% trifluoroacetic acid (TFA) in water were used as
the mobile phase, and a reversed-phase column (Atlantis dC18, 5 m, 2.1 by 150
mm; Waters) was used for separations. The detection and spectral characteriza-
tion of peaks were made with Empower software (Waters).
Samples of culture supernatants (5 l) were eluted with a linear gradient from
0 to 15% acetonitrile over 15 min, followed by an additional 5 min of elution with
100% acetonitrile and a further 10 min of equilibration under initial conditions
at a flow rate of 0.25 ml/min. For some analyses performed with a different
column (Atlantis T3, 3 m, 2.1 by 150 mm; Waters), the initial gradient was
prolonged to reach 20% acetonitrile in 20 min. Mass detection was done by
FIG. 2. Generation of mutants in thn genes. Shown are the organizations of chromosomal regions of the wild type and the mutant strains and
genetic analysis by Southern analysis (A and C) and by PCR (B and D). Only relevant restriction sites are indicated, and B indicates BamHI. The
gray arrow represents the mutated gene, and the black arrow indicates the aac(3)IV gene, encoding the apramycin resistance marker (apr cassette).
(A) Insertion of the apr cassette into the thnP coding region and Southern hybridization of BamHI-digested genomic DNA from the wild type (WT)
and the thnP::aac(3)IV mutant (M) using the 8.5-kb BamHI fragment as a probe. (B) Insertion of the apr cassette into the thnG coding region and
PCR analysis of genomic DNA from the wild type and the thnP::aac(3)IV mutant using oligonucleotides ThnG-R and ThnG-F. (C) Deletion of
the internal fragment of thnT and replacement with the apr cassette (see Materials and Methods) and Southern hybridization of BamHI-digested
genomic DNA from the wild type and the thnT::aac(3)IV mutant using pHZMRT as a probe. (D) Insertion of the apr cassette into the thnR
coding region and PCR analysis of genomic DNA from the wild type and the thnR::aac(3)IV mutant using oligonucleotides ThnR-R and ThnR-F.
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electrospray ionization in the positive mode, with an ionization voltage of 3 kV,
a cone voltage of 15 V, a cone temperature of 100°C, and a desolvation temper-
ature of 250°C.
Detection was performed spectrophotometrically at 309 nm for thienamycin
and at 264 nm for cephamycin C and also by selected ion recording (SIR) of the
protonated ions (m/z 273 for thienamycin and m/z 447 for cephamycin C). Other
molecular ions corresponding to putative intermediates were also detected in
some analyses.
RESULTS
An approximately 25.4-kb region of the S. cattleya chromo-
some (EMBL accession number AJ421798) encoding a series
of 22 genes, thnA to thnV, was first proposed (25) to participate
in thienamycin biosynthesis and regulation (Fig. 1C). We have
used a mutational approach for some thn genes as a way to
determine their involvement in the biosynthesis of the complex
carbapenem thienamycin. Together with previously generated
mutants of the structural genes thnL, thnN, and thnO (25),
additional ones were obtained here. All mutants were further
analyzed by searching for an accumulation of putative inter-
mediates to establish some steps of the biosynthetic pathway
leading to thienamycin molecule assembly.
Concerning transcriptional organization, the ThnI-regulated
genes appear to be organized into four operons driven by four
promoter regions whose in vivo functionality has been deter-
mined (28). PQ and PH (Fig. 1C) drive the expression of the
downstream genes as two monocistronic transcripts, termed
thnQ and thnH, respectively. PP drives the transcription of
thnP, thnO, thnN, thnM, and thnL as the pentacistronic operon
thnPONML, whereas PK drives the transcription of thnK, thnJ,
and thnI as the tricistronic operon thnKJI. Other putative pro-
moter sequences have also been identified for the ThnI-inde-
pendent genes (Fig. 1C) by the use of the BPROM bacterial
promoter prediction server (Softberry Inc., Mount Kisco, NY).
Upstream of the thnG coding region, and divergently oriented
to PH, a putative promoter sequence (PG) consisting of a 35
box at TTGCCT (score of 56) and a 10 box at CCGGA
TAGT (score of 16) was found. Another putative promoter
sequence (PE) is located upstream of the thnE initiation codon.
It consists of a 35 box at TTGACT (score of 26) and a 10
box at ACCTAGGCT (score of 61). An additional putative
promoter sequence has been identified in the thnT-cphU in-
tergenic region (PU), consisting of a 35 box at TTGACC
(score of 44) and a 10 box at GCCTACACT (score of 45).
Upstream of the thnV initiation codon, a putative promoter
sequence (PV) consisting of a 35 box at TTGTCC (score of
31) and a 10 box at CGTTATGAT (score of 73) was also
identified. The above-mentioned ThnI-dependent promoters
were not localized with this bioinformatic program, with the
unique exception of PH, consisting of a putative 35 box at
CTGCCG (score of 10) and a 10 box at ACTTACGCT
(score of 24).
Generation of mutants affected in thienamycin biosynthesis.
(i) Inactivation of thnP. The predicted thnP product consists of
484 amino acid residues with a molecular mass of 53,734 Da
(EMBL accession number CAD18984) and displays sequence
similarity with methyltransferases belonging to the radical S-
adenosylmethionine (SAM) superfamily (cl10028) and associ-
ated with the B12 binding domain (cd02068). Radical SAM
enzymes catalyze steps in the biosynthesis of many antibiotics.
ThnP also shows similarity to two putative methyltransferases
encoded in the thn cluster as well: ThnL (26% identity and
46% similarity) and ThnK (24% identity and 49% similarity).
To investigate the role of thnP in thienamycin biosynthesis,
a disruption mutant, thnP::aac(3)IV, was generated by insert-
ing the apramycin resistance cassette within the thnP coding
region (see Materials and Methods). Chromosomal DNA from
this mutant and the wild-type strain was digested and analyzed
by Southern analysis using the BamHI 8.5-kb fragment as a
probe. An 8.5-kb hybridizing band was detected in the wild-
type strain, whereas two positive signals of 4.9 and 5 kb were
detected in the mutant (Fig. 2A). Thienamycin production was
analyzed in culture supernatants of the thnP disruption mutant
after 5 days of growth by bioassays against the thienamycin-
sensitive and cephamycin-resistant strain S. aureus ATCC
6539P and also by HPLC-MS (Fig. 3B). An absence of thiena-
mycin production in this mutant demonstrated that thnP is
essential for thienamycin biosynthesis. However, the mutant
retained the ability to produce cephamycin, thus showing that
ThnP is not involved in cephamycin C biosynthesis.
(ii) Inactivation of thnG. The thnG gene product is a protein
of 263 amino acid residues with a molecular mass of 29,188 Da
(EMBL accession number CAD18975) and displays sequence
similarity to members of the phytanoyl-CoA dioxygenase
(PhyH) superfamily (cl02184). ThnG shares 32% identity
(45% similarity) with the deduced product of thnQ, another
gene belonging to the same family in the thn cluster. ThnG and
ThnQ are potential 2-oxoglutarate-dependent dioxygenases
proposed to catalyze the desaturation of the carbapenam bi-
cyclic ring to carbapenem, as was shown previously for Car
biosynthesis for CarC, which belongs to the same superfamily
of enzymes (30).
In order to understand the role of thnG in thienamycin
biosynthesis, a disruption mutant, thnG::aac(3)IV, was gener-
ated by inserting the apramycin resistance cassette within the
thnG coding region. Chromosomal DNAs from this mutant
and the wild-type strain were analyzed by a PCR amplification
reaction using the oligonucleotides ThnG-R and ThnG-F (Ta-
ble 1). As shown in Fig. 2B, a PCR product of about 2.0 kb was
obtained with the mutant, while for the wild type, the product
was 0.5 kb. The 1.5-kb increase in the size of the mutant was
due to the insertion of the apramycin resistance cassette, as
was verified by sequencing, thus confirming the replacement of
the wild-type gene by the mutated one. Analysis of culture
supernatants of the mutant after 5 days of growth by bioassay
and HPLC-MS analysis (Fig. 3C) revealed that the mutant still
produced thienamycin but at a higher yield than that of the
wild-type strain. Additional experiments were performed to
quantify thienamycin production at different times during
growth, both by bioassay and spectrophotometrically by signal
integration at 309 nm. These experiments confirmed a 2.5-fold
increase in thienamycin production for the mutant strain in
comparison with the wild-type strain (which produces around 1
g/ml). Furthermore, the accumulation of a compound with a
molecular mass corresponding to a putative intermediate in
the biosynthetic pathway was also detected in this mutant (see
below). However, the mutant retained the ability to produce
cephamycin at normal levels, thus showing that ThnG is not
involved in cephamycin C biosynthesis.
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Identification of genes not essential for thienamycin biosyn-
thesis. The finding that the regulatory gene cphU linked to the
thn cluster is involved in cephamycin C biosynthesis and not in
thienamycin biosynthesis raised the question of whether other
genes in the cluster initially considered to be involved in
thienamycin biosynthesis were not part of the thn cluster. In
order to redefine more precisely the right physical boundary of
the thn gene cluster, two novel mutants were independently
generated in the thnT and thnR coding regions within the S.
cattleya genome. The thnT gene is adjacent to the cephamycin
regulatory gene cphU. thnR is adjacent to thnQ, the distal gene
in this side of the cluster involved in thienamycin biosynthesis,
since it belongs to the ThnI regulon (27, 28).
(i) Generation of a thnT deletion mutant. The predicted
thnT gene product consists of 399 amino acid residues with a
molecular mass of 39,125 Da (EMBL accession number
CAD18988) and displays significant similarity to members of
the DmpA/ornithine acetyltransferase (OAT) superfamily of
aminopeptidases (cl00603). DmpA shows similarity in the cat-
alytic mechanism to N-terminal nucleophile (Ntn) hydrolases,
which are enzymes that catalyze the cleavage of amide bonds
through the nucleophilic attack of the side chain of an N-ter-
FIG. 3. MS and HPLC analyses of mutants affected in thienamycin biosynthesis. Shown are data for culture supernatants from the S. cattleya
wild-type strain (A), the thnI-disrupted mutant (B), the thnG-disrupted mutant (C), and the thnD-cphU deletion mutant (D). Thienamycin
detection was as follows: SIR at m/z 273 (1) and detection at 309 nm (2). Cephamycin C detection was as follows: SIR at m/z 447 (3) and detection
at 264 nm (4). The arrows indicate the retention times of the peaks corresponding to thienamycin (thn) and cephamycin C (cph). AU, arbitrary
units.
VOL. 55, 2011 THIENAMYCIN BIOSYNTHESIS IN STREPTOMYCES CATTLEYA 1643
 o
n
 February 24, 2015 by UO
V BIBLIO
TECA UNIVERSITARIA
http://aac.asm
.org/
D
ow
nloaded from
 
minal serine, threonine, or cysteine. Based on bioinformatic
database analysis, it was initially proposed that ThnT might be
involved in cysteine transferase during thienamycin biosynthe-
sis (25). Enzymatic assays have shown that recombinant ThnT
is able to hydrolyze pantetheine to yield cysteamine, and a
putative role in generating the cysteaminyl side chain in thiena-
mycin biosynthesis was proposed (12).
To uncover the role of thnT in S. cattleya, a deletion mutant
was generated in the chromosome by gene replacement. The
apramycin resistance cassette aac(3)IV was inserted within
the thnT coding region, generating a deletion mutant,
thnT::aac(3)IV (see Materials and Methods). Chromosomal
DNA from this mutant and the wild-type strain was digested
with BamHI. Southern blotting experiments were performed
by using the pUOMR12 construct as a probe. In addition to
8.5-, 6.1-, and 0.6-kb positive signals found in both strains, a
differential hybridizing band of 1.5 kb was detected for the
deletion mutant, whereas a 0.7-kb band was found for the wild-
type strain (Fig. 2C), confirming the replacement of the wild-
type gene by the mutated one. As a consequence of the mu-
tation, a 1.1-kb deletion was produced in the thnT coding
region (nucleotides 24,800 to 25,900 in the sequence) (EMBL
accession number AJ421798). Analysis of culture supernatants
of the mutant, after 5 days of growth, by bioassay against S.
aureus ATCC 6538P revealed that the thnT deletion mutant
was still able to produce thienamycin (data not shown). Bio-
assays against Escherichia coli ESS (sensitive to both thiena-
mycin and cephamycin C) showed a clear reduction in the halo
diameter in comparison to that of the wild-type strain (data not
shown), thus suggesting that the biosynthesis of cephamycin
was affected. HPLC-MS analysis (Fig. 4B) confirmed that this
mutant retained the ability to produce thienamycin but had
lost the ability to produce cephamycin. This result revealed
that ThnT is not essential for thienamycin biosynthesis and, as
previously shown for cphU, that it is involved in cephamycin C
biosynthesis.
(ii) Generation of a thnR disruption mutant. ThnR is a
protein of 240 amino acid residues and a molecular mass of
26,447 Da (EMBL accession number CAD18986), which dis-
plays sequence similarity with members of the Nudix hydrolase
superfamily (cd02883). This superfamily includes enzymes
found in organisms of all three kingdoms of life, and it cata-
lyzes the hydrolysis of nucleoside diphosphates linked to other
moieties, X. ThnR displays a well-conserved domain of
cd03426, coenzyme A pyrophosphatase (CoAse), which func-
tions by catalyzing the elimination of oxidized inactive CoA
TABLE 1. Primers used in this study
Primer Sequence (5–3)a Description
ThnG-F AGGTGCGCATCATCGGCCG Forward primer for thnG
ThnG-R TGGCGGGGCAGCGAATAGC Reverse primer for thnG
MR1-F ACGTAGATCTCGATGACCTCGTTCCCG Forward primer for thnT
MR1-R ACGTGCATGCGAACTCCCTTCAGCCCG Reverse primer for thnT
MR2-F ACGTGCGGCCGCTCCTCACCCGCGCCGTG Forward primer for thnT
MR2-R ACGTTCTAGACGCTCCGGCTGTGGGTG Reverse primer for thnT
ThnR-F TTCCGACCTGGCTGACCGGC Forward primer for thnR
ThnR-R AGCTCCCGCACCAGGAACCC Reverse primer for thnR
a The restrictions sites BglII (AGATCT), SphI (GCATGC), NotI (GCGGCCGC), and XbaI (TCTAGA) used for cloning are in boldface type.
FIG. 4. HPLC-MS analysis of mutants not affected in thienamycin biosynthesis. Shown are data for culture supernatants from the S. cattleya
wild-type strain (A), the thnT deletion mutant (B), and the thnR-disrupted mutant (C). Thienamycin and cephamycin detection (1, 2, 3, and 4)
is described in the legend of Fig. 3.
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that can inhibit CoA-utilizing enzymes. Although thnR does
not resemble any previously known antibiotic biosynthetic
gene, it was included in the thn cluster based on its physical
situation, surrounded by homologous biosynthetic and regula-
tory antibiotic genes (25). Enzymatic assays have shown that
recombinant ThnR is able to cleave CoA to 4-phosphopantethe-
ine, and a putative role in thienamycin biosynthesis was pro-
posed previously (12).
To more clearly define the thn cluster physical boundary and
learn more about the role of thnR in S. cattleya, a disruption
mutant was obtained for this gene. The thnR::aac(3)IV mutant
was generated by the insertion of the apramycin resistance
cassette within the thnR coding region. Chromosomal DNA
from the mutant and the wild-type strain was obtained and
analyzed by a PCR amplification reaction using the oligonu-
cleotides ThnR-F and ThnR-R as primers (Table 1). As shown
in Fig. 2D, a PCR product of about 2.0 kb was obtained for the
mutant, while for the wild type, the product was 0.5 kb. The
1.5-kb increase was due to the insertion of the apramycin
resistance cassette in the mutant, as was verified by sequencing,
thus confirming the replacement of the wild-type gene by the
mutated one. Analysis of culture supernatants of the mutant by
bioassay and HPLC-MS analysis (Fig. 4C) revealed that the
mutation in thnR has no effect on thienamycin or cephamycin
production. This indicates that thnR is not essential for thiena-
mycin or cephamycin biosynthesis and might represent the
physical boundary of the thienamycin gene cluster.
Cross-feeding experiments. Since antibiotics are usually the
products of stepwise linear biosynthetic pathways, it is often
possible to carry out cosynthesis tests between mutants blocked
at different steps in the pathway. This is based on the assump-
tion that intermediates accumulated by the blocked mutants
are freely diffusible and capable of being taken up by other
mutants grown in close proximity. Thus, a mutant blocked later
in the pathway (secretor) might accumulate an intermediate
that may be able to enter a mutant blocked earlier (convertor),
providing a missing intermediate for continuing synthesis in
the latter strain.
To establish cross-feeding relationships, cosynthesis analysis
of the nonproducing mutants in the thnL, thnN, thnO, and thnP
genes blocked in the thienamycin biosynthetic pathway was
carried out. Pairs of mutants were plated close to each other on
agar plates, and after incubation, strips were analyzed by using
S. aureus as an indicator strain to detect a restoration of thiena-
mycin production (see Materials and Methods). Wild-type S.
cattleya was used as a positive control, and the different mu-
tants were used as negative ones. Initially, several pairs of
mutants were found to show cross-complementation that re-
stored thienamycin production, and halos were found spanning
both mutants at the same time. This indicated that some in-
termediates were stable and were able to cross the cell mem-
brane and diffuse between cells and through the agar. After
establishing the conditions for each pair of mutants, distance
and time of incubation, one-way complementation was ob-
tained. As shown in Fig. 5, successful cross-feedings were ob-
served by the appearance of an inhibition zone in the thnL,
thnO, and thnN mutants. Five pairs gave a positive result: thnL
versus thnP, thnO versus thnL, thnN versus thnL, thnN versus
thnP, and thnN versus thnO. However, no cross-feeding was
detectable for the remaining pair, thnP versus thnO. The ability
of thnL, thnO, and thnN mutants to produce thienamycin in the
neighborhood of thnP; thnL; and thnO, thnL, and thnP, respec-
tively, demonstrates that the first mutant incorporates an in-
termediate secreted by the second one and converts it into
thienamycin. As outlined in Fig. 5, these results might provide
an indication of the possible order of the enzymatic steps in the
pathway, as follows: ThnN, ThnO, ThnL, and ThnP.
Identification of putative intermediates in thienamycin bio-
synthesis-blocked mutants by HPLC-MS. To investigate the
biosynthetic steps of the thienamycin pathway, phenotypic
analysis of the available thn mutants was performed by
HPLC-MS analysis. We explored the possibility of detecting
putative intermediates in the biosynthetic pathway by
HPLC-MS analysis of culture supernatants of all available non-
thienamycin-producing mutants. The production conditions
were previously described for thienamycin production by
growth in R5A liquid medium (minus glucose) (27). Samples
were taken at various times (4, 5, 6, and 7 days) during growth.
The mutants included in the analysis were the ones affecting
the following genes: thnN, thnO, thnP, thnL, and thnG. The
mutant blocked in the regulatory gene thnI, affected in the
expression of the ThnI-dependent genes, was also analyzed, as
it was still able to express the structural ThnI-independent
genes. The S. cattleya wild-type strain was used as a positive
control for the HPLC mass analysis. A thnD-cphU deletion
FIG. 5. Cross-feeding relationship of thn structural mutants. Co-
synthesis experiments were performed with thnN, thnL, thnO, and thnP
non-thienamycin-producing structural mutants. Agar strips from R5A
(minus sucrose) agar plates containing the mutants grown for 6 to 10
days at 28°C were used in the bioassays against thienamycin-sensitive
S. aureus strain ATCC 6538P. The inhibition zones indicate a restora-
tion of thienamycin biosynthesis due to the diffusional exchange of
accumulated intermediates. No cross-feeding was detectable in the rest
of the pairs. The wild-type strain was used as a positive control. L, N,
O, and P indicate mutants generated in genes thnL, thnN, thnO, and
thnP.
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mutant (Fig. 3D) was used as a negative control. This mutant
lacks most of the thn genes (from thnD up to thnT and the
promoter region and first 13 cphU codons) and is affected in
both thienamycin and cephamycin C production (L. E. Nun˜ez
et al., unpublished data).
The molecular ions included in the analysis (Fig. 6) were
selected according to different putative intermediates reported
in the literature. SIR detection of protonated ions was per-
formed at m/z 174, 168, 289, 245, 243, 257, 259, and 275 (25, 35)
and at m/z 154, 156, 168, and 170 (30). In addition, novel
combinations in the enzymatic step order corresponding to m/z
166, 168, 180, 182, 184, 198, 231, 303, and 319 were also
analyzed (Fig. 6). One of the major difficulties of this approach
was the low level of thienamycin production in the wild-type
strain (about 1 g/ml) and, consequently, of the putative in-
termediates. Despite this fact, two compounds of m/z 156 and
275 (Fig. 7) were detected by HPLC-MS analysis. Due to the
low level of production and the hydrophilic nature of the com-
pounds, which does not permit their solvent extraction from
the culture medium, there was not sufficient yield to allow
scale-up purification and nuclear magnetic resonance (NMR)
analyses. Nevertheless, according to the mutants and masses of
compounds detected, some of the peaks could be putatively
ascribed to specific compounds. A peak with m/z 156 was
detected in cultures of the thnL mutant (Fig. 7A) and at lower
levels in the wild-type strain and the thnP and thnN mutants as
well (however, it was absent in the thnD-cphU, thnI, and thnO
mutants). According to its mass, this compound could corre-
spond to carbapenam-3-carboxylic acid, one of the putative
intermediates proposed previously for the initial steps of
thienamycin biosynthesis (30). Another peak corresponding to
a product with m/z 275 was found to accumulate in the thnG
mutant (Fig. 7B). The molecular mass could correspond to
2,3-dihydrothienamycin, one of the proposed late intermedi-
ates in the thienamycin pathway (25, 35). However, no such
peak was detected for any of the remaining analyzed strains,
including the rest of the mutants and the wild-type strain.
DISCUSSION
The carbapenem group of -lactams is one of the most
therapeutically potent antibiotics currently available (24). Al-
though carbapenems are natural products, the clinically used
antibiotics are thienamycin derivatives produced by chemical
synthesis, since no fermentation procedures have been devel-
oped yet. This is due mainly to the low yields of thienamycin
production by the producing strains and to molecule instability.
Deciphering the biosynthetic pathway in order to facilitate its
metabolic manipulation might enable more efficient produc-
tion and the possibility of obtaining more stable derivatives.
This might also lead to the generation of novel carbapenems,
which are needed for the fight against emergent antibiotic-
resistant pathogens.
Thienamycin and its derivatives have the same carbapenem
nucleus as the simplest member of carbapenems, Car, whose
biosynthetic pathway has been extensively studied by both ge-
netics and biochemistry (4). Although not clinically useful it-
self, knowledge of Car biosynthesis has been of great help as a
FIG. 6. Chemical structures and molecular masses ([M  H]) of putative intermediates included in the MS analysis.
1646 RODRI´GUEZ ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 February 24, 2015 by UO
V BIBLIO
TECA UNIVERSITARIA
http://aac.asm
.org/
D
ow
nloaded from
 
model system for thienamycin biosynthesis, as they share pre-
cursors, glutamate (pyrrolidine ring) and acetate (-lactam
carbons), as well as core biosynthetic enzymes for bicyclic ring
assembly. However, the pathways to the C-2,C-6-substituted
carbapenems as thienamycin involve multiple enzymes. The
essential steps in the biosynthesis of Car in P. carotovorum are
catalyzed directly by three enzymes, CarABC (18, 23). Se-
quencing analysis of the thn gene cluster revealed the close
relationship of ThnE and ThnM to CarB and CarA, respec-
tively (25). The CarB and ThnE carboxymethylproline syn-
thases are members of the crotonase superfamily, which cata-
lyze pyrroline ring formation by the conversion of glutamate
semialdehyde (L-GSA) into trans-carboxymethylproline using
malonyl-CoA as a cosubstrate. There is evidence supporting
that ThnE catalyzes the formation of (2S,5S)-trans-carboxy-
methylproline from precursors with an efficiency similar to that
of CarB (13). The -lactam ring was proposed to be formed by
the -lactam synthetase ThnM in a way similar to that of CarA,
generating a carbapenam bicyclic ring (25). The oxidation of
carbapenam to carbapenem, and ring inversions, must take
place at some later point, as occurs in Car by the action of the
2-oxoglutarate-dependent dioxygenase CarC. Despite the lack
of a convincing CarC homologue in the thn gene cluster, it was
proposed that two members of the same family, ThnG and
ThnQ, might catalyze analogous reactions. These enzymes
have been proposed to be responsible for the coupled C-5
epimerization and C-2/C-3 desaturation of (2S,5S)-carbap-
enam to (5R)-carbapenem-3-carboxylate (13, 30). Recent stud-
ies of the genetics of thienamycin regulation in S. cattleya have
revealed that the thn genes display a different expression pat-
tern (27, 28). Interestingly, genes encoding the carbapenem
ring assembly enzymes (ThnE, ThnM, and ThnG/ThnQ) show
a completely different organization than those of their homo-
logues in P. carotovorum, as they are not adjacent and not
transcriptionally coupled (Fig. 1). Furthermore, they are dif-
ferentially regulated, since only thnM and thnQ are ThnI de-
pendent, whereas thnE and thnG display a ThnI-independent
regulation pattern.
Based on the results provided here for the characterization
of several thn mutants together with latest findings in the
literature for this area, we propose some enzymatic steps in the
thienamycin biosynthetic pathway (Fig. 8). As shown by
HPLC-MS analysis, a compound with m/z 156 ([M  H]),
which might correspond to carbapenam-3-carboxilic acid, has
been detected in some of the mutants (thnL, thnP, and thnN
mutants) as well as in the S. cattleya wild-type strain. Although
further investigations will be needed to address this question,
these results suggest that carbapenam-3-carboxilic acid might
be an intermediate in the biosynthetic pathway. Thus, bicyclic
nucleus formation would occur in the same order as that for
Car assembly, being the -lactam ring formed immediately
after the five-member ring. This contrasts with the initially
proposed pathway, in which a methylation reaction at C-6
would take place, immediately after the five-member ring is
formed and before the generation of the -lactam one (25, 35).
However, this result is in agreement with a proposed alterna-
tive pathway in which ThnE and ThnM catalyze sequential
steps, like CarB and CarA in P. carotovorum (30). The absence
of this compound in the thnI deletion mutant reinforces this
hypothesis, since it expresses thnE and not thnM. In fact, this
regulatory mutant behaves as a structural mutant blocked in
the enzymatic step that follows the ThnE reaction.
On the other hand, if carbapenam-3-carboxylic acid is an
intermediate in thienamycin assembly, the incorporation of the
first methyl group at C-6 to generate the hydroxyethyl side
chain of thienamycin would probably occur after ThnM syn-
thetizes the -lactam ring. The accumulation of a compound
with an m/z corresponding to carbapenam-3-carboxilic acid in
the thnL- and thnP-disrupted mutants is in agreement with this
hypothesis, although it should be pointed out that another
putative methyltransferase, ThnK, might contribute to this
process (25). The results of cosynthesis analysis of thienamy-
FIG. 7. Detection of putative intermediates by MS analysis. (A) SIR at m/z 156 ([M  H]) of culture supernatants of S. cattleya thnD-cphU
and thnL mutants. The peak indicated by an arrow putatively corresponds to carbapenam-3-carboxylic acid. (B) SIR at m/z 275 ([M  H]) of
culture supernatants of the S. cattleya wild type and the thnG mutant. The peak indicated by an arrow putatively corresponds to 2,3-dihydrothiena-
mycin.
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cin-nonproducing mutants have provided an indication of the
possible order of the ThnL and ThnP enzymatic reactions in
the pathway: since the thnP mutant restores thienamycin pro-
duction in the thnL mutant when growing in close proximity,
the thnP mutant appears to be blocked later in the pathway.
The phenotype of the thnG mutant is quite remarkable and
difficult to understand, as besides accumulating a putative in-
termediate in the pathway, the mutant also overproduces
thienamycin. First, the detection of a compound with m/z 275
([M  H]), corresponding to 2,3-dihydrothienamycin, in this
mutant suggests that ThnG might be responsible for the oxi-
dation reaction that converts the carbapenam to the carbap-
enem ring (Fig. 8). This is in agreement with one of the two
possibilities proposed previously for the last step in the thiena-
mycin pathway (25, 35). Second, the thienamycin production in
this mutant might be explained by the similarity between ThnG
and ThnQ, as they share 30% amino acid identity. As men-
tioned above, the encoding genes display a different regulation
pattern, and the thnQ monocistronic transcripts were found to
be five times more abundant than the monocistronic tran-
scripts for thnG (27). The function of both enzymes in the
thienamycin biosynthetic pathway has been the subject of mul-
tiple hypotheses (2, 13, 25, 30). A prominent feature of the role
of the 2-oxoglutarate-dependent oxygenases in -lactam bio-
synthesis pathways is their ability to catalyze more than one
reaction (15). One of the proposed roles of ThnG/ThnQ is to
catalyze the C-2/C-3 desaturation of the carbapenam nucleus
to carbapenem (13, 30), which takes place in two independent
enzymatic steps (35). In agreement with this, we can speculate
that the restoration of thienamycin production in the thnG
mutant might be the result of a partial complementation by
ThnQ, resulting in 2,3-dihydrothienamycin accumulation in
the mutant. This role for ThnQ indirectly suggests that the
early oxidation step converting the carbapenam ring to carbap-
enem might be carried out by ThnQ earlier on in the pathway.
In addition, ThnG was recently found to give rise to oxidative
carbapenem diversity being able to hydroxylate the C-6 car-
bapenem moiety in vitro (2). Third, the 2.5-fold increase in
thienamycin production observed for the thnG deletion mu-
tant, in comparison with the S. cattleya wild-type strain, might
be explained by a putative lack of expression of the down-
stream thnF gene as a consequence of the mutation. ThnF is an
acetyltransferase proposed previously to give rise to the S.
cattleya cometabolite N-acetylthienamycin through the acety-
lation of the reactive primary amine in thienamycin (12). Thus,
the lack of N-acetylthienamycin formation might explain the
thienamycin accumulation in this mutant in relation to the
wild-type strain.
Another controversial point in thienamycin biosynthesis is
the incorporation of the cysteaminyl side chain at C-2. It has
been long assumed that cysteine is the source of cysteamine
and is incorporated directly into the antibiotic (35). The au-
thors of that study also suggested an alternative branch path-
way leading to thienamycin after the incorporation of pantethe-
ine (through the formation of OA-6129 carbapenems). Some
recent reports on the enzymatic activities of recombinant
ThnT, ThnR, and ThnH have shown that they process in vitro
CoA through pantetheine to yield cysteamine (12). Gene ex-
pression analyses have shown that the genes encoding these
proteins are differentially regulated in S. cattleya, as only thnH
is ThnI dependent, while thnT and thnR are ThnI independent
(27). As deduced from the phenotypic analysis of the respec-
tive mutants of thnT and thnR, we provide evidence here sup-
porting that under our standard culture conditions, ThnT and
ThnR are not essential for thienamycin biosynthesis. Recom-
binant ThnT, shown previously in vitro to hydrolyze pantethe-
ine to cysteamine (12), appears to be required for cephamycin
biosynthesis, as deduced from the HPLC-MS analysis of the
thnT deletion mutant. ThnR, reported previously to cleave
CoA to 4-phosphopantetheine (12), is a member of the Nudix
hydrolase superfamily whose general role is to hydrolyze nu-
cleotide pools and to maintain cell viability, serving as surveil-
lance and “house-cleaning” enzymes. In this regard, thnR
might represent the physical boundary of this side of the
thienamycin gene cluster. Mutational analyses of two other
FIG. 8. Thienamycin biosynthetic pathway in S. cattleya and assign-
ment of functions to different genes.
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genes in the thn cluster, thnN and thnO, have revealed that they
are absolutely required for thienamycin biosynthesis (25), al-
though their role is still unknown. Based on its similarity to
GriC-GriD, a carboxylic acid reductase complex essential for
grixazone biosynthesis in Streptomyces griseus, it was proposed
previously that ThnN-ThnO may be responsible for the reduc-
tion of a carboxylic acid to the corresponding aldehyde in the
thienamycin pathway (33). A decarboxylation step occurs dur-
ing the generation of the cysteaminyl side chain after cysteine
incorporation in thienamycin biosynthesis (25, 35). Cross-feed-
ing relationships suggest that ThnN catalyzes an earlier step
than ThnO and that both ThnN and ThnO carry out reactions
previous to those of the ThnL and ThnP putative methyltrans-
ferases. In addition, the presence of the putative carbapenam-
3-carboxilic acid in the thnN-disrupted mutant suggests that
ThnN acts after the bicyclic ring is formed (although its ab-
sence in the thnO mutant is not in agreement with the cross-
feeding result). Conserved domain analysis of ThnN has shown
the presence of an amino acid adenylation domain
(TIGR01733), which can activate amino acids in nonribosomal
peptide synthetases. These enzymes are involved in the peptide
biosynthesis of antibiotics and other pharmacological mole-
cules of microbial origin (17). ThnO presents a conserved
domain belonging to the NAD(P)-dependent aldehyde dehy-
drogenase superfamily (cl11961). Although further investiga-
tions will be needed to address this question, and it is still a
matter of speculation, the involvement of ThnN-ThnO in gen-
erating the thienamycin cysteaminyl side chain from cysteine
might be a possibility.
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